Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|January 8, 2014
T-DM1 as a Treatment for Breast Cancer
Author(s)Edith A. Perez, MD
Edith A. Perez, MD, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Advertisement
Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Clinical Pearls:
- T-DM1 is a combination of trastuzumab and a chemotherapy agent all in one compound
- Once the drug is injected into the vein, T-DM1 finds the cells that overexpress HER2 and then places the chemotherapy inside the tumor cell
- The results of the MARIANNE trial, which will examine T-DM1 plus pertuzumab, T-DM1 with pertuzumab or placebo, and trastuzumab plus a taxane (docetaxel or paclitaxel) in patients with metastatic breast cancer, could be practice changing
Advertisement
Related to this article
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5